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a b s t r a c t
The chemokine receptor CCR5 is required for cellular entry bymany strains ofHIV, andprovides a potential
target for molecules, including antibodies, designed to block HIV transmission. This study investigates a
novel approach to stimulate antibodies to CCR5. Rabbits were immunised with chimaeric peptides which
encode a short fragment of the N-terminal sequence of CCR5, as well as an unrelated T cell epitope from
Tetanus toxoid. Immunisation with these chimaeric peptides generates a strong antibody response which
is highly focused on the N-terminal CCR5 sequence. The antibody to the chimaeric peptide containing
an N-terminal methionine also recognises the full length CCR5 receptor on the cell surface, albeit at
higher concentrations. Further comparison of binding to intact CCR5with binding to CCR5peptide suggestntibody
himaeric peptide
locking antibodies
that the receptor speciﬁc antibody generated represents a very small fragment of the total anti-peptide
antibody. These ﬁndings are consistent with the hypothesis that the N-terminal peptide in the context
of the intact receptor has a different structure to that of the synthetic peptide. Finally, the antibody was
able to block HIV infection of macrophages in vitro. Thus results of this study suggest that N-terminal
fragments of CCR5may provide potential immunogenswithwhich to generate blocking antibodies to this
receptor, while avoiding the dangers of including T cell auto-epitopes.
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i. Introduction
Classical vaccination strategies applied to HIV infection have
roved to be ineffective. A signiﬁcant proportion of antibody
gainst the virus is non-neutralising, and indeed some antibody
ay enhance viral infectivity [1,2] The majority of neutralising
ntibody is directed against the gp120 glycoprotein on the viral sur-
ace. This protein shows extensive variability, and most antibodies
re strain speciﬁc. Some cross-strain neutralising antibodies have
een reported [3,4] and efforts are in progress to focus the immune
esponse on the epitopes recognised by these antibodies. However,
lternative strategies to inhibit HIV are also of interest.
An alternative target for HIV blocking antibodies are the recep-
ors used by virus to gain entry into the cell. The CD4 molecules
lays a key role in T cell function, and antibodies against it are
ikely to be pathogenic. However, the CCR5 chemokine receptor
ffers a more attractive target. This receptor is absent in approx-
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mately 1% of the Caucasian population [5], and these individuals
how no gross symptoms of immunodeﬁciency, although recent
eports have suggested a possible role for CCR5 in mycobacterial
esponses [6] and West Nile virus infection [7]. CCR5 deﬁciency
s associated with almost complete protection against HIV infec-
ion [8,9] and even CCR5 heterozygous individuals, which show
aplotype insufﬁciency, show a slower progression to AIDS [10].
enetically determined overexpression of CCR5 ligand CCL3L1 is
lso associated with partial protection [11]. Finally, small molec-
lar weight CCR5 antagonists can block HIV entry, and one such
nhibitor is in clinical use [12]. Thus, CCR5 levels are quantitatively
nd qualitatively a key parameter in determining the course of HIV
nfection, and the subsequent development of AIDS.
Several groups have recently investigated the possibility of rais-
ng antibodies against CCR5 [13–17], and have used recombinant
roteins, recombinant viruses or synthetic cyclic peptides to pro-
Open access under CC BY license.ide proof of principal evidence that the strategy can work. The
afety of autoantigen driven vaccine strategies remains a cause for
oncern, however. A trial of therapeutic vaccination in Alzheimer
atients using the amyloid fragment A, was discontinued because
f adverse side effects attributed to the autoimmune response [18],
cine 2
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lthough the damage may have been due to autoimmune cellu-
ar rather than humoral responses. Cellular autoimmune responses
gainst the CCR5 receptor are likely to be pathogenic, since they
ay lead to elimination of dendritic cells, macrophages, T cells and
nyother cell typeswhich express this receptor. In this study, there-
ore, we explore the possibility of raising an immune response to
he CCR5 receptor, using a very short N-terminal fragment of the
eceptor, coupled to a well characterised epitope of tetanus tox-
id [19,20]. Since the immunogen contained seven amino acids of
CR5 sequence, thepossibility of including aCD4or CD8T cell auto-
pitope is avoided. The N-terminal sequence was chosen, since it
ay adopt a looser conﬁguration than the other extracellular loops.
Our study shows that this chimaeric peptide can indeed stim-
late antibody which recognises intact receptor, and that this
ntibody can reduce HIV infectivity in vitro. However, only a small
roportion of the anti-peptide antibody crossreacts with receptor,
uggesting that the N-terminal region of the native CCR5 receptor
ay be structurally distinct from the synthetic peptide immuno-
en.
. Methods
.1. Peptides
The sequence of the peptides used in this study are given below:
ll peptideswere synthesised by the Protein andPeptide Chemistry
epartment at Cancer Research UK. Purity was greater than 80%
s measured by HPLC. Peptide CCR5 was also supplied coupled to
eyhole Limpet Haemocyanin (KLH) via an additional terminal cys-
eine, using theprotocol describedbelow for bovine serumalbumin
BSA).
.2. Cell lines
U87 cells (a human glioma derived line) expressing CD4 and
CR5 (U87-CD4-CCR5) were obtained from Drs. Littman and
eng, via the Centralised Facility for AIDS Reagents (Repos-
tory Reference ARP069 and ARP072) (http://www.nibsc.ac.uk/
potlight/aidsreagent/) supported by EU Programme AVA/MRC
contract QLKZ-CT-1999-00609) and the UK Medical Research
ouncil. The cells weremaintained in selectionmedium (15% foetal
alf serum, DMEM) containing G418 (300g/ml) and puromycin
1g/ml, only for CCR5 expressing cells) as described in detail in
he data sheet for these cells lines.
The human glioma cell line NP2, expressing CD4 and CCR5 or
XCR4 [21],weremaintainedat37 ◦Cand5%CO2 in10%FCS,DMEM.
Macrophages were prepared by culture of monocytes isolated
rom healthy volunteers in human serum and M-CSF as described
reviously [22]. The studywasapprovedby the jointUCL/UCLHNHS
rust Human Research Ethics Committee and written informed
onsent was obtained from all participants. This protocol yields
acrophages at >95% purity by morphology and CD14 staining.
.3. Immunisations
Two sets of immunisations were carried out at the Biological
ervices Unit, UCL.
.3.1. Experiment 1
Three rabbits were immunised with each peptide CCR5.1 andCR5.2. Primary immunisations were carried out with peptide
total 1mg) emulsiﬁed in complete Freund’s adjuvant (CFA, Sigma),
t four subcutaneous sites. The rabbits were boosted at day 15, 22,
9 and 42 with peptide emulsiﬁed in incomplete Freund’s adju-
ant (IFA). All rabbits were sacriﬁced and exsanguinated by cardiac
2
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uncture on day 63. Serum (preimmune, test and ﬁnal) were col-
ected using standard methods, and stored at −20 ◦C until needed.
.3.2. Experiment 2
Three rabbits were immunised with peptide CCR5.5 conjugated
o KLH. Primary immunisations were carried out with conjugate
Total 0.4mg) emulsiﬁedwith CFA, at four subcutaneous sites. Rab-
its were boosted on days 14, 21, 28 and 44 with KLH/peptide
onjugate (Total 0.2mg) emulsiﬁedwith IFA. A further three rabbits
ere immunised with peptide CCR5.5 bound to magnetic strepta-
idin beads (M-PVA SAV1, Chemagen). Beads (25mg) were washed
n PBS, and mixed with peptide CCR5.5 (100g). After 15min, the
uspension of beads was mixed with adjuvant (Imject® ALUM,
ierce), and shaken vigorously to produce an emulsion. Immu-
isation schedule was as for CCR5.5/KLH, except that the same
ead/peptide suspension was used for all immunisations. A total
f 100g peptide was injected at each immunisation. All rabbits
ere sacriﬁced and exsanguinated by cardiac puncture on day 63.
erum (preimmune, test and ﬁnal) were collected using standard
ethods, and stored at −20 ◦C until needed.
.4. Conjugation of peptides to BSA
CCR5.3 and CCR5.4 were conjugated to BSA using sulphosuc-
inimimidyl 4-(N-maleimidomethyl) cyclohexane (Sulpho-SMCC),
igma–Aldrich, Poole, Dorset). Brieﬂy, 0.6mol BSA were reacted
ith 17mol Sulpho-SMCC in phosphate buffered saline (PBS)
or 1h. The BSA/SMCC conjugates were exchanged into sodium
hosphate buffer (0.1M, pH 6) using PD-10 desalting column
AmershamBiosciences).Meanwhile, 10molof eachpeptidewere
issolved in 1ml borate buffer (0.1M, pH 8) and reduced by the
ddition of sodium borohydride (130mol); excess borohydride
as destroyed by brief acidiﬁcation. Each reduced peptide solution
asmixedwithhalf theBSA/SMCC, and incubatedovernight at 4 ◦C.
he ﬁnal conjugate was dialysed against PBS and stored frozen in
liquots.
.5. Conjugation of BSA/peptide to Sepharose
Fifteen to 20mg of each peptide/BSA conjugate was coupled to
NBr-activated Sepharose 4B (Sigma–Aldrich) using the manufac-
urer’s instructions. The coupledmatrix was extensively washed in
igh (pH 8) and low (pH 4) pH buffers, and stored in PBS/azide until
sed for afﬁnity puriﬁcation.
.6. Antibody puriﬁcation
CCR5.3/BSA/Sepharose (approximately 1ml) was washed with
0ml PBS. 5–10ml serum from immunised rabbits wasmixedwith
he Sepharose and incubated for 20min to allow binding to the
mmunoadsorbent. The ﬂow through was then collected, and the
olumnwas washed with a further 20ml PBS. Bound antibody was
luted with 5ml glycine solution (0.1M, pH 2.5), and 400l frac-
ions collected. 6l Tris solution (1M)was added to each collecting
ube to bring the pH back to neutral as rapidly as possible. Each
raction was tested for CCR5.3 binding activity by ELISA, and frac-
ions containing the highest titres (typically fractions 4–8) were
ooled, and ﬁlter sterilised. For functional assays, the puriﬁed anti-
ody was exchanged into complete culture medium using PD-10
olumns, following manufacturer’s instructions..7. Antibody radiolabelling
Forty micrograms purifed antibody was mixed with 0.2mCi
aI125 (Amersham) and 10g chloramine T (Sigma) and incubated
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or 60 s. The reaction was terminated by adding sodiummetabisul-
hite (10mg), and excess I125 quenched by addition of potassium
odide (10mg). Labeled protein was puriﬁed from reactants by col-
mn chromatography on a PD10 column (Amersham Biosciences)
ccording to manufacturers’ instructions, and stored in PBS at
◦C until used. Speciﬁc activity was about 1.2×106 cpm per g
rotein.
.8. ELISA
96 well ELISA plates (Nunc) were coated with BSA/peptide
onjugates (05–1g/ml) in coating buffer (0.1M sodium bicarbon-
te, pH 8.5), overnight at 4 ◦C. All wells were washed (washing
uffer PBS 0.1% Tween-20) and blocked by addition of 2% low
at milk (Tesco) in PBS for at least 2h at room tempera-
ure.
Sera or antibodies were diluted in washing buffer and added at
he concentrations shown, for 1.5–3h at room temperature. Bound
ntibody was detected using alkaline phosphatase coupled sheep
nti-rabbit (Sigma) antibody (1:2000 dilution) and substrate (PNPP
AST, Sigma). Results are shown either as optical density (405nm)
r as log3 titre. The titre is calculated as the largest dilution factor
hich gives a reading above twice the mean background optical
ensity (no ﬁrst layer).
.9. Flow cytometry
U87 transfected cells (5×104) were incubated in 50l PBS con-
aining 10% goat serum (Sigma) and 0.1% sodium azide (blocking
uffer) for 30min at 4 ◦C. Test or control sera at various dilu-
ions (in blocking buffer) were added, and incubated for 2–3h
t 4 ◦C. Cells were washed and bound antibody detected using
oat anti-rabbit FITC (R&D Systems). A positive control monoclonal
at anti-human CCR5 was obtained from Drs. J. McKeating and
. Shotton, via the Centralised Facility for AIDS Reagents (Repos-
tory Reference ARP3214.1) (http://www.nibsc.ac.uk/spotlight/
idsreagent/).
.10. Functional assays of blocking activity
.10.1. Inhibition of HIV on transfected NP2 cells
5×103 NP2 cells stably expressing CD4 and either CCR5 or
XCR4 were seeded into a 96-well plate 24h prior to treat-
ent with the CCR5 antagonist TAK779 [23] (10M, NIBSC, UK),
uriﬁed CCR5 antibody or control antibody. The cells were incu-
ated at 37 ◦C for 1h after which the existing medium was
eplaced with fresh supplemented medium with antibody and
00 focus-forming units of virus. The HIV-1 strains SF162, BaL
nd the primary isolate SL2 were used in these experiments.
fter 2h at 37 ◦C the cells were washed twice and medium con-
aining antibody was placed back onto the cells for a further
8h. The cells were then ﬁxed in ice cold acetone–methanol
1:1) and stained in situ for p24 expression as described previ-
usly [24]. The blocking experiments with NP2 cells were also
epeated using the protocol described below for macrophages,
ith very similar results to those obtained with the initial proto-
ol.
.10.2. Inhibition of HIV on primary human macrophages
Macrophage cultures were pre-incubated with afﬁnity puriﬁed
abbit anti-CCR5 immunoglobulin or pre-immune rabbit IgG for 1h
t roomtemperature and then inoculatedwithHIV-1BaL (passaged
n primary human macrophages and titred on NP2 cells) using
oubling dilutions of virus prepared in medium with anti-CCR5 or
n
(
e
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ontrol antibody. The inoculumwas removed after overnight incu-
ation and the intracellular p24 staining assessed 3–4 days later as
escribed [24].
. Results
CCR5.1 peptide incorporates the ﬁrst seven amino acids of the
ull length sequence of human CCR5, followed by a linker/spacer
nd an MHC class II promiscuous T cell epitope from tetanus tox-
id [19,20]. Remarkably, there is no information in the literature
bout whether the methionine at position 1 is still present or is
leaved before CCR5 is exported to the cell membrane. A second
eptide, in which the methionine was absent was therefore tested
n parallel. Sera were ﬁrst tested by ELISA, using as target anti-
en peptides CCR5.3 and CCR5.4, which contain the ﬁrst twelve
mino acids of the CCR5 receptor (Fig. 1), with (CCR5.3) or without
CCR5.4) the initial methionine. Each peptide was conjugate via an
dditional C-terminal cysteine to BSA. A representative ELISA for all
ix sera showed that all rabbits gave strong antibody responses to
eptides containing the CCR5 sequences to which they had been
mmunised (Fig. 1), with titres of greater than 20,000 (9, log3).
itres rose rapidly after 1 or 2 boosts (Fig. 1b), and appear to be
eaching a plateau by the time the rabbits are sacriﬁced. The sera
rom the rabbits immunised with methionine-containing peptide
referentially recognised the target peptide with an N-terminal
ethionine (Fig. 1c, left), while the sera from rabbits immunised
ith peptide without methionine preferentially recognised pep-
ides without methionine (Fig. 1c, right).
The sera were then tested for binding to CCR5 by ﬂow cytome-
ry, using CCR5 transfectants as targets. A summary showing mean
uorescence intensities at a variety of concentration for all six
abbits is shown in Fig. 2a, and a representative ﬂuorescence his-
ogram for one rabbit (rabbit 2) is shown in Fig. 2b. Two of the
hree sera recognising themethionine-containing N-terminal pep-
ide bound CCR5 transfected cells, but not to controls. In contrast,
one of the sera from the three rabbits immunised with the trun-
ated peptide bound to CCR5. All further experiments used the
ethionine-containing sequence.
The immunogenicity of the peptides may have been limited
y the presence of only a single T helper epitope in the immu-
ising peptide, and/or by the fact that peptide immunogens are
ntrinsically univalent. Two additional sets of immunisation were
herefore carried out with peptide CCR5.5, which is identical to
CR5.1, except for the additionof aC-terminal biotinylated cysteine.
he C-terminal cysteine was used to couple to a strong “carrier
rotein”, KLH, and the conjugate emulsiﬁed in Freund’s adjuvant
as used to immunise rabbits 7–9. In parallel, the biotin moiety
as used to couple to inert streptavidin-coated magnetic beads,
nd the beads were resuspended in Alum adjuvant and used to
mmunise rabbits 10–12. The titres of all sera at the time the rab-
its were sacriﬁced tested against CCR5.3 is shown in Fig. 3. The
itreswere generally somewhat lower than those obtainedwith the
rst set of immunisations,with the lowest titres obtained following
ead/Alum immunisation. However, in all cases the titres were at
east 100-fold higher than control or preimmune sera, which gave
itres of less than 4 (log3, 100). The six sera were further tested
or binding to CCR5 receptor as above (Fig. 3b). None of the three
era from rabbits immunised with KLH conjugate showed signiﬁ-
ant binding to the transfectants. In contrast two of three rabbits
mmunised with CCR5.1 conjugated magnetic beads showed sig-
iﬁcant binding to CCR5 transfected cells (Fig. 3b), but not controls
not shown).
The results shown in Figs. 1–3 demonstrate a very large differ-
nce between the titre of anti-peptide antibody as measured by
LISA and asmeasured by binding to intact receptor by ﬂow cytom-
B.M. Chain et al. / Vaccine 26 (2008) 5752–5759 5755
Fig. 1. Anti-peptide antibody responses in rabbits immunisedwith peptides CCR5.1 and CCR5.2. (a) The sequences of peptides used for immunisation and ELISA, showing the
sequences derived from CCR5, the linker sequence and the Tetanus toxoid T cell epitope sequence. (b) Antisera from the ﬁnal bleed from rabbits immunised with CCR5.1 (left
panel) or CCR5.2 (right panel) were diluted 1:100 in blocking buffer, and then diluted over a range of threefold dilutions as shown. Antibody reactivity was tested by ELISA
against peptides CCR5.3 (left panel) and CCR5.4 (right panel) as described in Section 2.8. Each point shows the mean of duplicate wells. Each rabbit serum was tested at least
t t time
o tides
w ach se
a
e
a
s
c
S
c
a
t
p
t
b
o
w
e
C
p
t
d
b
t
c
h
r
t
e
u
S
c
o
m
u
T
F
m
t
a
p
o
s
t
t
b
4hree times. (c) Antibody titre from prebleed (PB) or test bleeds collected at differen
f 100 or less are shown as zero. (d) Cross reactivity of antisera to heterologous pep
hile rabbits 4–6were immunisedwith CCR5.2 (without N-terminalmethionine). E
s shown. Each point shows mean of three sera with standard error of the mean.
try. To investigate this further, the antibody with anti-peptide
ctivity was puriﬁed from serum of rabbit 2 (ﬁrst set of immuni-
ations) and rabbit 10 (second set of immunisations) by afﬁnity
hromatography, using peptide CCR5.3/BSA conjugate bound to
epaharose 4B. The titre of antibody remained high after puriﬁ-
ation (Fig. 4a), although when adjusted for volume of puriﬁed
ntibody, recovery of active antibody was about 50% for both sera.
In order to test whether the anti-peptide antibody fraction con-
ained the antibody which bound to the CCR5 receptor, the two
uriﬁed antibody preparations were further tested for binding
o CCR5 expressing transfectants (Fig. 4b). Both puriﬁed samples
ound speciﬁcally to CCR5 transfectants, but not to control cells. In
rder to estimate the proportion of total peptide binding antibody
hich bound to CCR5, a puriﬁed antibody sample was absorbed on
xcess target CCR5 cells (2×107) or on control cells not expressing
CR5, and then tested for binding to CCR5 (Fig. 4c) and to CCR5.3
eptide (Fig. 4d). Adsorption on receptor expressing cells removed
he majority of receptor binding activity as expected (Fig. 4c), but
id not signiﬁcantly alter the peptide binding ability as measured
y ELISA (Fig. 4d). Thus receptor binding activity can be attributed
o a small proportion of anti-peptide binding antibody.In order to obtain more quantitative ﬁgures for antibody con-
entration and antibody afﬁnity, puriﬁed antibody was labeled to
igh speciﬁcity (approximately 1.5×106 cpm/g protein) by chlo-
amine T iodination. Approximately 50% of this activity bound
o CCR5.3/BSA/Sepharose beads, the remaining 50% representing
s
a
as postimmunisation as shown. Each point shows themean of duplicate wells. Titres
. Rabbits 1–3 were immunised with peptide CCR5.1 (with N-terminal methionine)
rum (ﬁnal bleed)was then tested against the homologous and heterologous peptide
ither non-speciﬁc protein which copuriﬁed from the afﬁnity col-
mn, or antibody damaged/destroyed by the iodination procedure.
peciﬁc binding to CCR5 transfectants was measured, either by
omparing binding to control cellswithout CCR5, or by the addition
f a large excess of unlabeled antibody. In three separate experi-
ents, less than 0.2% of the activity bound to transfected cells, even
nder optimal conditions of cell numbers/antibody concentration.
his low% binding is consistent with the binding data shown in
ig. 4c/d. The level of binding was too low to allow any accurate
easurements of afﬁnity/antibody concentration.
Although binding of antibody to CCR5 required large concen-
rations of antibody, we tested both unpuriﬁed sera and puriﬁed
ntibody inHIVneutralisation assays. Inhibition experiments using
rimary macrophage cultures as targets, showed strong inhibition
f HIV BaL infection (Fig. 5). In contrast, experiments using several
trains and NP2 CCR5 transfectants showed only 10–20% inhibi-
ion in infectivity compared to control (not shown). In comparison
he CCR5 inhibitor TAK779 gave inhibition of around 50%, ranging
etween 20 and 70%.
. DiscussionThe primary objective of this study was to test the hypothe-
is that a short N-terminal fragment of the CCR5 would stimulate
ntibodies which recognise the intact receptor on the cell surface,
nd to characterise these antibodies. The results suggest that the
5756 B.M. Chain et al. / Vaccine 26 (2008) 5752–5759
Fig. 2. Anti-CCR5 antibody responses in rabbits immunised with peptides CCR5.1 and CCR5.2. Final bleed antisera from rabbits 1–6 were tested for binding to CCR5+/CD4+
U87 cells (diamonds) or control CD4+ U87 cells (squares) by ﬂow cytometry. (a) Mean ﬂuorescent intensity at various dilutions for each rabbit. This experiment has been
repeated three times. (b) A representative histogram for prebleed (ﬁlled histogram) or ﬁnal bleed (solid line) for rabbit two serum, tested against CCR5+/CD4+ U87 cells (top
panel) or control CD4+ U87 cells. Each serumwas tested by ﬂow cytometry at least four times. (c) Control staining of amonoclonal anti-CCR5 (solid line) from the Centralized
AIDS Repository or isotype control (ﬁlled histogram).
Fig. 3. Antibody responses in rabbits immunised with peptide CCR5.5. (a) Sequence of CCR5.5. (b) Anti-peptide titre in ﬁnal bleeds from rabbits 7–12, measured by ELISA
using CCR5.3 peptide as target. Rabbits 7–9 were immunised with CCR5.5/KLH conjugate with CFA, rabbits 10–12 were immunised with CCR5.5 peptide coupled to magnetic
beads with Alum. Ctrl shows the results using rabbit serum from an immunised rabbit. Asterisk shows titre <100. The ﬁgure shows one representative experiment, from at
least three with each serum. (c) Final bleed antisera from rabbits 7–12were tested for binding to CCR5/CD4+ U87 cells by ﬂow cytometry. Each panel showsmean ﬂuorescent
intensity at dilutions of 1:10, 1:30, 1:90 and 1:270 for each rabbit. Ctrl shows the results using sera from an unimmunised rabbit. The ﬁgure shows one representative
experiment, from at least three with each serum.
B.M. Chain et al. / Vaccine 26 (2008) 5752–5759 5757
Fig. 4. Puriﬁcation of antibody from serum. (a) Anti-peptide binding activity of unpuriﬁed serum (A), ﬂow through from afﬁnity column of peptide CCR5.3 (B), and pooled
eluate from afﬁnity column (C) from rabbit 2 and rabbit 10. The titre of each sample was measured by ELISA using CCR5.3 as target. The puriﬁed antibody preparations were
ﬁrst adjusted to a concentration of 400g/ml. Asterisk indicate titre less than 100. (b) The puriﬁed antibody preparations, or an equal concentration of puriﬁed rabbit Ig
were tested for binding to CCR5/CD4 expressing U87 cells or control CD4 expressing U87 cells by ﬂow cytometry. Top two panels shows representative histograms of rabbit
2 puriﬁed antibody (80g/ml solid line) or control Ig (80g/ml, shaded) staining of CCR5+CD4+ U87 cells (left) or control CD4+ U87 cells (right). Bottom two panels show
Mean Fluorescent Intensity at different concentrations of puriﬁed antibody from sera of rabbit 2 (diamonds), rabbit 10 (squares) or control rabbit Ig (triangles), tested either
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87 cells (squares) or 2×107 CD4+ U87 cells (triangles) for 1h at 4 ◦C. The cells we
t different concentrations of protein. The ﬁgure shows results for one of two exper
o peptide CCR5.3 by ELISA.
asic hypothesis is correct, but suggest that the three-dimensional
onformation of this domain may have structural constraints not
reviously appreciated.
The basic strategy uses a chimaeric immunogen containing a
hort N-terminal sequence of CCR5 to act as the B cell immunogen,
nd a C-terminal tetanus toxoid T helper cell epitope, separated
y a four amino acid linker region. Immunisation with these chi-
aeric peptides successfully generated a strong antibody response
o a peptide coding the N-terminal sequence of CCR5. The antibod-
es generated were highly focused on the N-terminal itself, since
nclusion or removal of an additional methionine generated antis-
ra with minimal crossreactivity.
Although numbers of animals tested were too small for statisti-
al analysis, no antisera to the methionine-less peptide recognised
he intact receptor, suggesting that this amino acid is retained at
he cell surface. Although CCR5 protein has not been sequenced,
hese results are consistentwith the knownpreference ofmethion-
ne aminopeptidase, which cleaves methionine inefﬁciently where
he adjacent amino acid has a large side chain (e.g. aspartic acid in
his example) [25]. Similarly, a methionine at position 1 is retained
n the three-dimensional structure of rhodopsin, a G protein cou-
led receptorhomologueofCCR5 [26]. This observation raises some
uestions about recent attempts to determine or model structures
v
u
w
m
sntibody (40g protein) from rabbit 2 serum was adsorbed on 2×10 CCR5+CD4+
oved by centrifugation and the supernatant tested for binding by ﬂow cytometry
s. (d) The same two samples of adsorbed antibody as in (c) were tested for binding
or the CCR5 N-terminal peptide in complex with HIV gp120, since
n these studies the N-terminal methionine is generally absent
27,28].
Three different immunogens were used in this study, the chi-
aeric peptide alone (with CFA), the chimaeric peptide coupled to
LH (with CFA), and the chimaeric peptide coupled to streptavidin-
oatedmagnetic beads (withAlum).All three stimulatedgood titres
f anti-peptide antigen, and there was no apparent advantage to
ncorporating additional T cell epitopes by coupling to KLH. Lower
itres of anti-peptide antibody were obtained using Alum as adju-
ant, consistent with the known weaker adjuvant activity of Alum
ompared to CFA. However, other factors, such as the concentra-
ion of peptide, and the inﬂuence of magnetic beads may also have
layed a role, and these different variables need to be analysed
urther.
Serum from four rabbits detected cell surface CCR5 by ﬂow
ytometry. The concentration of antibody required was much
igher than that required todetect peptide byELISA (microgram/ml
ersus nanogram/ml). We hypothesised that the antibody is made
pof twopopulationswithdifferent speciﬁcities, onemajor species
hich recognises the peptide, but not the intact protein, and a
inor species which recognises both. In support of this hypothe-
is, absorptionwith CCR5 expressing cells at least for antibody from
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Rig. 5. Inhibitory activity of anti-CCR5 antibodies on HIV infectivity. Human macro
uriﬁed antibody (80g/ml) or control rabbit Ig. (A) Representative p24 staining af
nd S.E.M., one experiment of three).
ne rabbit, decreases the titre of cell binding antibody signiﬁcantly,
ut does not detectably change the titre of anti-peptide activ-
ty. Furthermore, absorption of radiolabeled antibody with CCR5
xpressing cells only removes about 0.1–0.2% of the total labeled
opulation, although at least 50% can still bind peptide-coupled
epharose beads. If correct, the hypothesis suggests that the N-
erminal peptide of CCR5 may have a more well-ordered structure
hanpreviously supposed.Analternativeexplanation is thatCCR5 is
ost-translationallymodiﬁedon the cell surface. Indeed some tyro-
ine residues are known to be sulphated in intact CCR5, including
yrosine at position 3 [29].
Interestingly, serum from two of the three rabbits immunised
ith CCR5.5/beads/Alum reacted well with CCR5, despite showing
ower total anti-peptide titres than those immunised with pep-
ide/CFA. Further studieswill be required todeterminewhether this
s due to the presentation of the peptide on the surface or beads, or
hether it reﬂects the different adjuvants used in each case.
We tested the ability of the antibodies to block HIV entry and
eplication, in both transfected cell lines, and primary human
acrophage cultures. Unsurprisingly, the antibodies were poor
nhibitorsofHIV infectivity asmeasuredonNP2CCR5 transfectants,
hich had very high levels of receptor expression (not shown) and
ere difﬁcult or impossible to saturate. In contrast, the antibodies
howed a reasonably good level of inhibitionwhen tested using pri-
ary macrophage targets. The reasons for this difference were not
xplored, but a plausible hypothesis is the extremely low level of
CR5 receptor expression on the primary macrophages compared
o the transfected cell lines (not shown).
In conclusion, this study demonstrates that very short linear
eptide epitopes, which cannot code for intact T cell auto-epitopes,
ay be used to generate an antibody response to the CCR5 protein.
hese results thus complement several other reports of stim-
lation of antibodies to CCR5 which block HIV entry/infection,
sing recombinant proteins or synthetic peptides as immunogenscultures were infected with HIV BaL at various MOIs in the presence of anti-CCR5
ays of culture. (B) Average % of p24 positive cells/well of triplicate cultures (mean
13,14,16]. Stimulation of anti-CCR5 antibodies has, therefore, been
hown to be an effective way to prevent HIV infection, at least
n principal. Further studies will be needed to test whether the
trategy outlined here will successfully break tolerance in an auto
ntigen setting, whether development of autoantibody is associ-
tedwith any pathology, andwhether immunisation efﬁciency can
e increased so as to stimulate antibody in a large majority of the
opulation at risk.
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